Rocket Lab is firing on all cylinders operationally, yet its share price is being battered by two powerful headwinds: a torrent of insider share sales and the gravitational pull of SpaceX’s long-anticipated initial public offering. The stock, which traded near €99.40 on Monday after a 4% bounce, remains roughly 29% below the all-time high it touched in late May. Adding to the pressure, the S&P index committee has declined to fast-track SpaceX into the S&P 500, dashing hopes of immediate index-fund inflows into the broader space sector.
Record Backlog and Surging Revenue
The company’s financial trajectory tells a far more upbeat story. First-quarter 2026 revenue surged 63.5% year over year to $200.3 million, while gross margin expanded to 38.2%. The contract backlog hit a record $2.2 billion, underpinned by a $90 million award from the U.S. Space Force and ongoing commitments under the Space Development Agency’s Tracking Layer program. Rocket Lab’s spacecraft systems division now accounts for 68% of total revenue, with launch services providing strategic leverage, particularly in defense and hypersonic applications. The company’s overall manifest lists more than 70 contracted missions.
A recent $60 million acquisition of Motiv Space Systems, a robotics firm that supplied hardware for NASA Mars missions, further bolsters Rocket Lab’s technology portfolio. For the current quarter, management has guided revenue in the range of $225 million to $240 million — another step up.
Neutron Nears Its Moment of Truth
The pivotal catalyst remains the Neutron rocket, a partially reusable medium-lift vehicle designed to carry up to 13 tonnes to low Earth orbit. First flight is scheduled for the fourth quarter of 2026, positioning Rocket Lab as a direct competitor to SpaceX’s Falcon 9 for constellation deployments and medium-sized government missions. The company has already cleared a key technical hurdle: the Archimedes engine, which will power the first stage in a nine-chamber configuration, passed qualification tests at NASA’s Stennis Space Center in late 2025.
However, the road to launch has not been without setbacks. A tank rupture during a test campaign at Wallops Flight Facility forced engineering adjustments to the first-stage propellant tank. CEO Peter Beck confirmed those revisions are complete, with integration of the Archimedes engines now under way. The maiden flight itself is not expected to generate meaningful revenue; rather, it is a proof-of-concept. Significant Neutron-related earnings are unlikely before 2027 or 2028, yet the market has already begun pricing in that future potential.
Should investors sell immediately? Or is it worth buying Rocket Lab?
A short-term catalyst arrives on June 10, when Rocket Lab plans to launch the suborbital mission “HASTE | Curveball” from Wallops Island under the Hypersonic Accelerator program for the U.S. Department of Defense.
Insider Selling Spree Raises Eyebrows
Despite the strong operational backdrop, insider trading patterns are flashing a cautionary signal. In early June, multiple executives sold shares worth approximately $18 million in aggregate. Director Alexander Slusky alone offloaded 60,000 shares for nearly $9 million, while President Marvin Clevenger sold 3,500 shares worth roughly $500,000. All transactions were executed through pre-arranged 10b5-1 trading plans, which are designed to shield insiders from accusations of trading on material non-public information.
Yet the scale and consistency of the selling are striking. Over the past 12 months, Rocket Lab has recorded 116 insider sales — and not a single insider purchase. While technically compliant, such a lopsided pattern can weigh on sentiment, particularly when combined with external sector dynamics.
SpaceX IPO Casts a Long Shadow
The broader space sector is bracing for a capital reallocation as SpaceX’s IPO, rumored for June 12, draws near. Investors are reshuffling positions ahead of the listing, driving volatility across publicly traded space stocks. Rocket Lab has not been immune: the stock is down roughly 9% for the week and trades at around €95.50, though it still shows a year-to-date gain of about 47% (and a near-fourfold increase over 12 months).
The Neutron opportunity, meanwhile, may have opened a rare competitive window as Blue Origin deals with a launch-site outage, leaving Rocket Lab the only U.S. alternative to SpaceX in the medium-payload segment. Whether the company can capitalize on that window will become clear only when the rocket lifts off — scheduled for the waning months of 2026. Until then, the tussle between strong fundamentals, insider exits, and the SpaceX IPO spectacle will continue to shape the stock’s trajectory.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from June 8 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 8.
Rocket Lab: Buy or sell? Read more here...
